Is NCT06561152 recruiting in Palo Alto, CA?

Yes, NCT06561152 is currently recruiting participants at its Palo Alto, CA location. This refractory acute myeloid leukemia clinical trial is actively enrolling qualified participants.

Is participation in this Palo Alto clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Refractory Acute Myeloid Leukemia Clinical Trial in Palo Alto, CA

Q: How do I join the refractory acute myeloid leukemia clinical trial in Palo Alto?

To join this clinical trial in Palo Alto, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Who Can Participate

Inclusion Criteria

Documented diagnosis of relapsed or refractory acute myeloid leukemia (AML) according to World Health Organization (WHO) 2022 criteria

Expression of CD123 by either flow cytometry or immunohistochemical staining with no minimum threshold for positivity

Must have received initial therapy with venetoclax in combination with a hypomethylating agent (either azacitidine or decitabine) with no subsequent therapy unless mutations in the IDH or FLT3 genes. If mutations in the IDH or FLT3 genes, treatment with IDH or FLT3 inhibitors after initial failure of venetoclax plus HMA is allowed, but not required.

Age ≥ 18 years of age

Albumin ≥ 3.2 g/dL at time of screening (note that albumin supplementation is not permitted to enable eligibility)

Left ventricular ejection fraction ≥ 50%

No clinically significant abnormalities on 12-lead electrocardiogram (ECG) including: complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \>250ms, or QTcF (Friderica's method) \>450ms in 3 successive measurements

Stated willingness to comply with all study procedures and availability for the duration of the study

Females of reproductive potential need to either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption prior to starting treatment, during the study therapy, and for 30 days after last dose of study therapy

For males of reproductive potential: agreement to use of condoms

Adequate hepatic/renal function defined as: Hepatic function: total bilirubin ≤ 1.5 x ULN (unless attributable to Gilbert's disease or leukemic involvement) AND AST or ALT ≤ 3 x ULN Renal function: creatinine clearance \> 30 mL/minute, calculated by Cockcroft Gault formula

Women of childbearing potential must have a negative urine or serum pregnancy test

Ability to understand and the willingness to provide written informed consent.

Exclusion Criteria

Prior therapy apart from Venetoclax in combination with a hypomethylating agent, or Venetoclax in combination with a hypomethylating agent followed by monotherapy with IDH or FLT3 inhibitors

Patients who received systemic anti-cancer therapy \<14 days prior to their first day of study drug administration.

Patients who received systemic anti-cancer therapy \<14 days prior to their first day of study drug administration. Concurrent hydroxyurea will be allowed. Hydroxyurea use will be allowed only during the first cycle if needed for disease control.

Significant cardiac disease (any NYHA Class 3 or 4 CHF, uncontrolled angina, history of MI, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension, or clinically significant arrhythmias not controlled by medication)

Any uncontrolled bacterial, fungal, viral or other infection.

Known HIV+ or active hepatitis B or C infection, defined as positive viral load for HBV or HCV or a positive surface antigen (HBsAg) test for hepatitis B.

The patient has persistent clinically significant toxicities Grade \>/= 2 from previous therapies not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue).

The patient has an active malignancy and/or cancer history that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of study entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with study team before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.

The patient has uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.

The patient has known active or suspected CNS disease. If suspected, CNS disease should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.

The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (\</= 10 mg/day).

Received allogenic stem cell transplant prior to the treatment.

The patient has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.

Pregnant or breast feeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT06561152) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Refractory Acute Myeloid Leukemia Treatment Options in Palo Alto, CA

If you're searching for refractory acute myeloid leukemia treatment options in Palo Alto, CA, this clinical trial (NCT06561152) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced refractory acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all refractory acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

Refractory Acute Myeloid Leukemia Clinical Trial in Palo Alto, CA

Expert Care in Palo Alto

IRB Approved

No-Cost Care

Apply for This Palo Alto Location

Why Participate?

Simple Process

About This Refractory Acute Myeloid Leukemia Study in Palo Alto